semaglutide 2.4 | Description, Uses, & Side Effects Wegovy was approved by the Food and Drug Administration (FDA) in 2021 and is marketed by Novo Nordisk Trial designs for SUSTAIN 2-4

Since our formation in 2013, weve supported countless individuals to achieve their weight loss goals, and were perfectly placed to do the same for you

Roche's CT-388 (dual GLP-1/GIP, acquired via Carmot) is structurally in the same position tirzepatide will occupy once Retatrutide reaches market: a credible, better-tolerated, second-tier asset competing on price and formulary access rather than on efficacy

A healthcare professional will assess your medical history, current health, and weight loss goals before deciding whether GLP-1 medication for weight loss is appropriate for you

Unlike GLP-1 drugs, it works within the bodys natural hormonal pathways, making it a low-risk, accessible option for those looking to optimize their diet